{
    "2021-08-28": [
        [
            {
                "time": "",
                "original_text": "明看并购 | 恒瑞医药：前面有万春",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "并购",
                        "万春"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "13亿引入抗癌药 恒瑞医药加速创新与国际化转型",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "抗癌药",
                        "创新",
                        "国际化",
                        "13亿"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}